TRDA
Entrada Therapeutics, Inc. NASDAQ Listed Oct 29, 2021$7.09
+4.11%
vs $6.81
Mkt Cap $293.3M
52w Low $5.02
18.8% of range
52w High $16.03
50d MA $9.48
200d MA $9.44
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.2x
ROE
-47.0%
P/FCF
-2.3x
RSI (14)
50.30
ATR (14)
$0.45
Beta
-0.15
50d MA
$9.48
200d MA
$9.44
Avg Volume
538.4K
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
CIK (SEC)
Phone
857 520 9158
6 Tide Street · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 16.03 | -57.5% | -57.3% | -0.1% | +2.3% | +1.7% | +2.8% | — |
| Feb 26, 2026 | AMC | -1.32 | -0.94 | +28.8% | 12.79 | +1.1% | -6.7% | -2.1% | +1.5% | +5.5% | -7.0% | — |
| Nov 6, 2025 | AMC | -1.04 | -1.06 | -1.9% | 6.95 | -1.7% | -0.6% | +5.1% | +6.1% | +4.0% | +9.6% | — |
| Aug 6, 2025 | AMC | -0.86 | -1.04 | -20.9% | 5.95 | +0.0% | -10.9% | -2.1% | -3.3% | +2.8% | +3.1% | — |
| May 8, 2025 | AMC | -0.78 | -0.42 | +46.2% | 8.62 | +0.6% | -2.8% | +5.3% | -1.4% | -8.4% | +1.9% | — |
| Feb 27, 2025 | AMC | -0.66 | 0.03 | +104.5% | 11.98 | -1.5% | -0.3% | -5.1% | -3.0% | -3.7% | -1.5% | — |
| Nov 5, 2024 | AMC | -0.67 | -0.35 | +47.8% | 18.62 | +6.1% | +0.2% | +3.1% | +3.1% | +0.4% | -0.5% | — |
| Aug 13, 2024 | AMC | 0.14 | 1.55 | +1007.1% | 15.81 | +1.2% | +0.1% | +2.8% | +1.7% | -0.1% | +2.5% | — |
| May 7, 2024 | AMC | -0.59 | 0.68 | +215.3% | 13.88 | -2.6% | +1.2% | +2.2% | -0.1% | -2.0% | +1.0% | — |
| Mar 13, 2024 | AMC | -0.07 | -0.29 | -314.3% | 12.71 | -2.8% | -4.0% | +4.8% | -2.9% | +2.3% | +5.1% | — |
| Nov 7, 2023 | AMC | -0.74 | 1.02 | +237.8% | 16.99 | +0.1% | -0.7% | -4.5% | +3.2% | -1.4% | +2.7% | — |
| Aug 8, 2023 | AMC | -0.43 | -0.78 | -81.4% | 15.40 | +0.3% | -0.6% | +2.2% | +4.9% | -6.4% | +4.1% | — |
| May 10, 2023 | AMC | -0.77 | -0.21 | +72.7% | 11.93 | +0.3% | +1.8% | +2.9% | +2.4% | +2.2% | +3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $6.85 | $6.63 | -3.2% | -0.1% | +2.3% | +1.7% | +2.8% | -6.7% |
| Apr 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.15 | $13.31 | +1.2% | +5.6% | -0.2% | +3.4% | -1.9% | -3.9% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.02 | $11.01 | -0.1% | +0.2% | +3.4% | -1.1% | +0.0% | +1.7% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $7.98 | -0.4% | +2.9% | -6.7% | -0.9% | -1.6% | +2.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.43 | -1.4% | -5.4% | -3.1% | +0.5% | -8.9% | -1.0% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.85 | $13.04 | +1.5% | -5.7% | -0.8% | -0.3% | -0.3% | -5.1% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.33 | $13.39 | +0.5% | +1.7% | +3.2% | -3.6% | -4.0% | -0.6% |
| Nov 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.1% | +3.1% | +0.4% | -0.5% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.1% | +3.1% | +0.4% | -0.5% |
| Aug 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.52 | $16.62 | +0.6% | +2.4% | -1.2% | -2.3% | +7.2% | +1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.81 | $16.00 | +1.2% | +0.1% | +2.8% | +1.7% | -0.1% | +2.5% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.24 | $14.15 | -0.6% | +3.7% | -4.5% | +0.5% | +0.6% | +0.5% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.78 | $12.78 | +0.0% | -2.9% | +2.3% | +5.1% | +1.4% | +1.3% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.49 | $11.51 | +0.2% | +8.8% | +1.8% | +2.4% | -0.4% | +3.3% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.61 | $13.56 | -0.4% | +6.0% | +3.5% | -0.3% | +4.2% | +4.4% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.40 | $15.44 | +0.3% | -0.6% | +2.2% | +4.9% | -6.4% | +4.1% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.94 | $16.82 | -0.7% | -12.1% | -3.0% | -1.4% | -2.2% | +10.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.32 | $13.43 | +0.8% | -4.3% | -6.5% | -1.3% | -6.3% | +4.0% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.50 | $14.62 | +0.8% | +4.8% | -5.1% | -3.2% | -1.3% | +7.0% |
| Nov 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.84 | $19.33 | -2.6% | -3.2% | -0.9% | +1.5% | -1.4% | -1.1% |
| Aug 16 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.80 | $12.59 | -1.6% | -3.1% | +2.9% | +1.1% | +0.6% | +1.1% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.05 | $5.89 | -2.6% | -0.8% | +4.5% | +5.1% | +6.5% | -3.7% |
| Nov 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $24.13 | $24.52 | +1.6% | +11.9% | +7.1% | +4.8% | -1.7% | +2.4% |
| Nov 23 | TD Cowen | Maintains | Outperform → Outperform | — | $30.40 | $30.01 | -1.3% | -20.6% | +11.9% | +7.1% | +4.8% | -1.7% |
| Nov 23 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.40 | $30.01 | -1.3% | -20.6% | +11.9% | +7.1% | +4.8% | -1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | Zeiher Bernhardt GDir | — | Buy | 5,000 | $5.86 | $29K | 5,000 | +3.96% | +3.67% |
| May 4, 2026 | Dowden Nathan JOff | President & COO | Sell | 15,000 | $15.33 | $230K | 198,588 | -0.25% | +2.34% |
| May 4, 2026 | Sethuraman NatarajanOff | President, Research & Develop. | Sell | 25,907 | $15.39 | $399K | 216,317 | -0.25% | +2.34% |
8-K · 5.02
!!! Very High
Entrada Therapeutics, Inc. -- 8-K 5.02: Executive Change
Jun 10
8-K · 7.01
! Medium
Entrada Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Entrada Therapeutics updated its investor presentation, suggesting the company is refreshing its messaging to stakeholders, though the filing provides no details on material developments or strategic changes.
May 19
8-K · 2.02
!! High
Entrada Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Entrada Therapeutics reported quarterly earnings results via press release filing, providing investors with updated financial performance and operational metrics.
May 7
8-K
Entrada Therapeutics, Inc. -- 8-K Filing
Entrada Therapeutics received a positive Data Monitoring Committee recommendation to advance ELEVATE-44-201 to a higher 12 mg/kg dose, signaling clinical progress in 2026 that could strengthen the company's pipeline momentum.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,256,013 | $16M | New | Mar 2026 |
| 2 | Stepstone Group Lp | 761,277 | $10M | — | Mar 2026 |
| 3 | Millennium Management | 519,356 | $7M | Added | Mar 2026 |
| 4 | Morgan Stanley | 520,502 | $5M | Reduced | Dec 2025 |
| 5 | Jones Hill Capital Lp | 374,010 | $5M | New | Mar 2026 |
| 6 | Acadian Asset Management Llc | 333,169 | $4M | Added | Mar 2026 |
| 7 | Northern Trust Corp | 234,992 | $3M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 220,494 | $3M | New | Mar 2026 |
| 9 | Woodline Partners Lp | 215,977 | $3M | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 215,018 | $3M | Reduced | Mar 2026 |
| 11 | Longaeva Partners L.p. | 204,978 | $3M | New | Mar 2026 |
| 12 | Renaissance Technologies Llc | 202,084 | $3M | Reduced | Mar 2026 |
| 13 | Bnp Paribas Financial Markets | 181,148 | $2M | — | Mar 2026 |
| 14 | Nuveen, Llc | 175,648 | $2M | Added | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 87,453 | $1M | Reduced | Mar 2026 |
| 16 | Aqr Capital Management Llc | 79,493 | $1M | Added | Mar 2026 |
| 17 | D.e. Shaw & Co | 79,047 | $998K | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 76,427 | $965K | Reduced | Mar 2026 |
| 19 | Quantinno Capital Management Lp | 71,018 | $896K | Added | Mar 2026 |
| 20 | Jane Street Group, Llc | 85,662 | $881K | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$293.3M
Enterprise Value
$44.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.96x
P/S
51.12x
P/FCF
-2.26x
EV/EBITDA
—
Shares Out
41.4M
Financials (TTM)
Revenue
$5.7M
Net Income
-$166.1M
EBITDA
-$164.9M
Free Cash Flow
-$129.6M
Op Cash Flow
-$128.5M
EPS Basic
$-3.47
EPS Diluted
$-4.00
EPS Forward
$-3.98
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$377.4M
Total Liab.
$71.2M
Total Equity
$306.1M
Cash
$295.7M
LT Debt
$46.8M
Book Value/Sh
$7.40
Debt/Equity
0.17x
Current Ratio
12.53
Quick Ratio
12.53
Returns & Growth
ROE
-47.0%
ROA
-38.1%
ROIC
-43.7%
Rev Growth YoY
-87.9%
EPS Growth YoY
-297.2%
Price Returns
2W
+3.5%
1M
-47.6%
3M
-40.7%
6M
-31.2%
12M
-7.0%
Technicals
52W High
$16.03
52W Low
$5.02
50d MA
$9.48
200d MA
$9.44
RSI (14)
50.30
ATR (14)
$0.45
Beta
-0.15
Avg Volume
538K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.00
High
$21.00
Low
$13.00
Median
$20.00
Data updated apr 27, 2026 5:30am
· Source: financialmodelingprep.com